TKIs
Showing 1 - 25 of 455
Called ROCURS, to Learn About COVID-19 Related Outcomes in
Active, not recruiting
- Malignant Solid Tumors
- +2 more
- Non-TKIs
- +3 more
-
Whippany, New JerseyBayer
Feb 2, 2023
Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine Trial in Nanjing (Trastuzumab Emtansine (T-DM1))
Recruiting
- Advanced Breast Cancer
- +2 more
- Trastuzumab Emtansine (T-DM1)
-
Nanjing, Jiangsu, ChinaJiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Nov 5, 2023
NSCLC, EGF-R Positive NSCLC Trial in Wuxi (Parimparib, Chemotherapy drug, Targeted Therapy Agent)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- EGF-R Positive Non-Small Cell Lung Cancer
- Parimparib
- +2 more
-
Wuxi, Jiangsu, ChinaAffiliated Hospital of Jiangnan University
Jan 30, 2023
A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib
Recruiting
- Non-small Cell Lung Cancer (NSCLC)
- +4 more
-
Guangzhou, Guangdong, ChinaCancer Center, Sun Yat-sen University
Oct 25, 2022
Knowing and Treating Kosaki/Penttinen Syndromes
Not yet recruiting
- Kosaki Overgrowth Syndrome
- Penttinen Syndrome
-
Dijon, FranceCHU Dijon Bourgogne
Jul 18, 2023
Tyrosine Kinase Inhibitors in Trastuzumab Emtansine Resistant
Recruiting
- Breast Cancer
- TKIs
-
Nanjing, Jiangsu, ChinaJiangsu Provincial People's Hospital
Feb 7, 2022
Withdrawal or Reduction TKIs in CML-CP
Recruiting
- MMR on 12 Month
- withdrawal TKIs or halve TKIs
-
Guangzhou, Guangdong, ChinaNanfangH
Sep 2, 2021
Safety of ICIs and TKIs Therapy for HCC
Recruiting
- Hepatocellular Carcinoma
- +2 more
- Lenvatinib Oral Product
- +2 more
-
Wuhan, Hubei, ChinaTongji Hospital, Tongji Medical College, Huazhong University of
Jun 11, 2022
NSCLC With EGFR Mutation Trial in Mexico City (Glutamine plus L. reuteri)
Recruiting
- Non-Small Cell Lung Cancer With EGFR Mutation
- Glutamine plus L. reuteri
-
Mexico City, MexicoInstituto Nacional de Cancerologia de Mexico
May 2, 2023
TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone
Completed
- Hepatocellular Carcinoma
- TACE-HAIC
- +3 more
-
GuangZhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Sep 8, 2022
Study Conducted Among Patients With CML
Completed
- Chronic Myeloid Leukemia
- Tyrosine Kinase Inhibitors (TKIs)
-
East Hanover, New JerseyNovartis Investigative Site
Jul 25, 2022
Olverembatinib, Chronic Myeloid Leukemia, Chronic Phase, Tyrosine Kinase Inhibitors Trial in Shenzhen (olverembatinib)
Recruiting
- Olverembatinib
- +2 more
-
Shenzhen, Guangdong, ChinaShenzhen Second People's Hospital
Jul 26, 2022
Lung Cancer Trial (Lazertinib 240 mg)
Approved for marketing
- Lung Cancer
- Lazertinib 240 mg
- (no location specified)
Feb 15, 2022
Lung Cancer, Non-small Cell, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial in Changsha (Genomic profiles detection,
Recruiting
- Lung Cancer, Non-small Cell
- +4 more
- Genomic profiles detection
- circulating tumor DNA detection
-
Changsha, Hunan, ChinaDepartment of Oncology, The Second Xiangya Hospital, Central Sou
Oct 25, 2022
Advanced NSCLC With MET Mutations Trial in United States (Tepotinib)
Recruiting
- Advanced Non-Small Cell Lung Cancer With MET Mutations
-
Aurora, Colorado
- +3 more
Jun 27, 2022
PD-1 Immunotherapy, VEGFR-TKI, Sarcomatoid Carcinoma Trial in Shanghai (Camrelizumab Combined With Apatinib)
Recruiting
- PD-1 Immunotherapy
- +3 more
- Camrelizumab Combined With Apatinib
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 1, 2022
Chronic Myeloid Leukemia, Chronic Phase, Withdrawal;Drug Trial in Czechia (Imatinib withdrawal, Dasatinib, Nilotinib)
Recruiting
- Chronic Myeloid Leukemia, Chronic Phase
- Withdrawal;Drug
- Imatinib withdrawal
- +2 more
-
Brno, Czechia
- +7 more
Aug 24, 2022
NSCLC Stage IV, EGFR T790M Trial in Shanghai (3rd generation EGFR-TKI, Consolidative SBRT)
Recruiting
- NSCLC Stage IV
- EGFR T790M
- 3rd generation EGFR-TKI
- Consolidative SBRT
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Feb 19, 2021
Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer Trial (SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin +
Not yet recruiting
- Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
- SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab
- +2 more
- (no location specified)
Nov 12, 2021
Nsclc, EGFR Activating Mutation, EGF-R Positive NSCLC Trial in Hong Kong (Pembrolizumab, Lenvatinib, Pemetrexed)
Recruiting
- Nsclc
- +5 more
- Pembrolizumab
- +3 more
-
Hong Kong, Hong KongQueen Mary Hospital
Nov 25, 2021
Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory Trial in Worldwide (Radotinib HCl)
Recruiting
- Chronic Myeloid Leukemia, Chronic Phase
- +3 more
- Radotinib HCl
-
Uijeongbu-si, Gyeonggi-do, Korea, Republic of
- +17 more
Jan 3, 2022
